MDR1 genotype-dependent regulation of the aldosterone system in humans

被引:14
作者
Zolk, Oliver
Jacob, Johannes
Pahl, Andreas
Fromm, Martin F.
Schmieder, Roland E.
机构
[1] Univ Erlangen Nurnberg, Dept Med Nephrol & Hypertens 4, D-91054 Erlangen, Germany
[2] Univ Erlangen Nurnberg, Inst Clin & Expt Pharmacol & Toxicol, D-91054 Erlangen, Germany
关键词
ABCB1; aldosterone; blood pressure; polymorphism;
D O I
10.1097/01.fpc.0000239969.46594.d0
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objective Aldosterone plays a major role in the development of both hypertension and heart failure. As aldosterone is a substrate of the ABCB1 (P-glycoprotein) efflux transporter, whose expression and activity has been shown to be linked to the ABCB1 3435C- T polymorphism, we tested the impact of the ABCB1 3435C -> T polymorphism on aldosterone disposition, blood pressure, cardiac structure, and kidney function. Methods A homogenous group of 116 young, white male Caucasian individuals with normal or mildly to moderately elevated, but never treated blood pressure was included. Blood pressure was compared between individuals with ABCB1 3435 CC, CT, and TT genotypes. Moreover, genotype-dependent differences in basal and angiotensin II-stimulated serum aldosterone, cardiac structure, and kidney function were evaluated. Results Of the 116 volunteers, 35 had the CC, 51 the CT and 30 the TT genotype. At baseline, no significant genotype-dependent differences in serum aldosterone were observed. After infusion of angiotensin II, the increase in aldosterone serum concentration was significantly higher in the TT group than that in the CT and CC groups (CC + 11 +/- 35, CT + 18 +/- 48, TT + 45 +/- 50 pg/ml, P=0.012). Systolic and diastolic blood pressure, left ventricular structure, and function and baseline renal function were not significantly different. After additional oral sodium load (5g/day over 1 week) urinary sodium excretion was found to be increased in individuals with the CC or CT genotype only but not in those with the TT genotype (CC + 71 +/- 83, CT + 52 +/- 114, TT - 11 +/- 98 mmol/day, P=0.005). Conclusion The present study demonstrates that the ABCB1 3435 genotype affects angiotensin II-stimulated serum aldosterone levels and salt-stimulated urinary sodium excretion. Although blood pressure and cardiac structure were unchanged in this young study population, our findings indicate a new link between MDR1 genotype and the aldosterone system in humans.
引用
收藏
页码:137 / 144
页数:8
相关论文
共 38 条
[31]   Association of the P-glycoprotein transporter MDR1C3435T polymorphism with the susceptibility to renal epithelial tumors [J].
Siegsmund, M ;
Brinkmann, U ;
Schäffeler, E ;
Weirich, G ;
Schwab, M ;
Eichelbaum, M ;
Fritz, P ;
Burk, O ;
Decker, J ;
Alken, P ;
Rothenpieler, U ;
Kerb, R ;
Hoffmeyer, S ;
Brauch, H .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (07) :1847-1854
[32]  
SIERSBAE.K, 1971, LANCET, V1, P1133
[33]  
SUGAWARA I, 1988, CANCER RES, V48, P1926
[34]   FURTHER CHARACTERIZATION OF THE HUMAN ADRENAL-DERIVED P-GLYCOPROTEIN RECOGNIZED BY MONOCLONAL-ANTIBODY MRK-16 REACTING WITH ONLY HUMAN P-GLYCOPROTEIN [J].
SUGAWARA, I ;
HAMADA, H ;
NAKAHAMA, M ;
OKAMOTO, S ;
TSURUO, T ;
MORI, S .
JAPANESE JOURNAL OF CANCER RESEARCH, 1989, 80 (12) :1199-1205
[35]   CELLULAR-LOCALIZATION OF THE MULTIDRUG-RESISTANCE GENE-PRODUCT P-GLYCOPROTEIN IN NORMAL HUMAN-TISSUES [J].
THIEBAUT, F ;
TSURUO, T ;
HAMADA, H ;
GOTTESMAN, MM ;
PASTAN, I ;
WILLINGHAM, MC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (21) :7735-7738
[36]  
UEDA K, 1992, J BIOL CHEM, V267, P24248
[37]   Effect of low-density lipoprotein cholesterol on angiotensin II sensitivity - A Randomized trial with fluvastatin [J].
van der Linde, Nicole A. J. ;
Sijbrands, Eric J. G. ;
Boomsma, Frans ;
van den Meiracker, Anton H. .
HYPERTENSION, 2006, 47 (06) :1125-1130
[38]   Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability [J].
Wang, DX ;
Johnson, AD ;
Papp, AC ;
Kroetz, DL ;
Sadée, W .
PHARMACOGENETICS AND GENOMICS, 2005, 15 (10) :693-704